
Strides Pharma Global Pte. Limited, secures USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg. The medication, used for partial seizures and neuropathic pain, is bioequivalent to Neurontin Tablets. With a market size of US$140Mn, this approval strengthens the company's Gabapentin portfolio, complementing existing capsule approvals.
Like
Save
Share